Back to results

CompletedPhase 3

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

NCT00105508

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Birmingham, Alabama, United States

+30 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2004-09-30
Enrollment: 506 participants
Sponsor: EMD Serono
Purpose: treatment

Locations (31)

Birmingham, Alabama, United States
Huntsville, Alabama, United States
La Jolla, California, United States
Oxnard, California, United States
Sacramento, California, United States
Englewood, Colorado, United States
Danbury, Connecticut, United States
Farmington, Connecticut, United States
Jacksonville, Florida, United States
Jacksonville, Florida, United States
Maitland, Florida, United States
St. Petersburg, Florida, United States
Decatur, Georgia, United States
Chicago, Illinois, United States
Springfield, Illinois, United States
Des Moines, Iowa, United States
New Orleans, Louisiana, United States
Scarborough, Maine, United States
Boston, Massachusetts, United States
Southfield, Michigan, United States
Edison, New Jersey, United States
New Hyde Park, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
Durham, North Carolina, United States
Oklahoma City, Oklahoma, United States
Pittsburgh, Pennsylvania, United States
Brentwood, Tennessee, United States
South Ogden, Utah, United States
Spokane, Washington, United States
Milwaukee, Wisconsin, United States

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia — TrialFind